Sage Therapeutics' SAGE-718 Gets FDA ODD; Bullish View On TeraWulf
- October 18th, 2023
- 716 views
Shares of Sage Therapeutics, Inc. (Nasdaq: SAGE), a leading biopharmaceutical company specializing in neurological and neuropsychiatric disorders, surged over 5% in pre-market trading after the company said that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to SAGE-718, a potential treatment for Huntington’s disease (HD).
HD, a rare and progressive neurodegenerative condition, impacts an estimated 40,000 U.S. adults annually, with severe cognitive effects.
$SAGE was trading at $21.05 in pre-market, up $1.41 (7.18%).
In other news, Stifel has initiated coverage on TeraWulf Inc. (Nasdaq: WULF), an infrastructure-focused bitcoin mining company, with a Buy rating and set a price target of $3.
Based on Tuesday's closing price of $1.24, the assigned price target implies a potential upside of $1.76 or approximately 141.94% for $WULF, according to the investment banking firm's view.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
September 23rd, 2026
FTC Endorses Education Department Proposal to Expand Higher Education Accreditation Options
September 22nd, 2026September 18th, 2026FTC Takes Action to Prevent Anticompetitive Arrangement in Beretta, Ruger Deal
September 16th, 2026Why Opponent Preparation Matters for Post-Graduate Athletes
September 16th, 2026
Member Login